Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in Severe Chronic Heart Failure
NCT00176332Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2004
- Countries
- 1
- Sponsor
- Leipzig University
- Modality
- Orthosteric Ligands
- Drugs
- rosuvastatin
- Conditions
- chronic heart failure (CHF)
01
Overview
Phase 2, randomised trial in chronic heart failure (CHF) comparing Rosuvastatin with Placebo (2 arms). Primary endpoints: Inflammation in the blood and the skeletal muscle at 3 months, Postnatal vasculogenesis at 3 months and 1 more. Started Mar 2004; status: completed.
02
Design
2 arms- Study design
- Randomized
Rosuvastatin
3 months of rosuvastatin treatment
Placebo
3 months of placebo treatment
03
Who it enrols
Patients with severe chronic heart failure (NYHA III/IV), LVEF <30%, and peak oxygen uptake <20 mL/min/kg, excluding those with hepatic or renal dysfunction, insulin-dependent diabetes, arterial hypertension, or muscle disease.
04
Endpoints
Primary
Inflammation in the blood and the skeletal muscle
Postnatal vasculogenesis
Endothelial function of the radial artery
Secondary
Peak oxygen uptake
Left ventricular function
Beyond the preview
Go deeper on NCT00176332.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176332.